Transdiagnostic Internet- and mobile-based intervention for the prevention of depression and anxiety

Conditions

Subclinical depression and subclinical anxiety F32 F41.9 F41.1 F41.0

Zarski AC, Weisel KK, Berger T, Krieger T, Schaub MP, Berking M, Görlich D, Jacobi C, Baños R, Botella C, Herrero R, Ebert DD.

2025-10-01

10.1038/s41746-025-01990-8

Internet-based indicated prevention of anxiety and depression disorder onset three-arm randomized clinical trial

Zarski, Anna-Carlotta, Weisel, Kiona K., Berger, Thomas, Krieger, Tobias, Schaub Michael, P. et al. (12 authors)

Universität Zürich, ZORA2025-10-01

10.5167/uzh-280626

Efficacy and cost-effectiveness of guided and unguided internet- and mobile-based indicated transdiagnostic prevention of depression and anxiety (ICare Prevent): A three-armed randomized controlled trial in four European countries.

Weisel KK, Zarski AC, Berger T, Krieger T, Schaub MP, Moser CT, Berking M, Dey M, Botella C, Baños R, Herrero R, Etchemendy E, Riper H, Cuijpers P, Bolinski F, Kleiboer A, Görlich D, Beecham J, Jacobi C, Ebert DD.

2018-04-1544 citations

10.1016/j.invent.2018.04.002

Interventions

Group 1: Intervention group A: Guided self-help online training consisting of 7 modules, which take about 45-60 minutes each to complete with an additional booster session 4 weeks after completion of

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Signed consent form, subclinical symptoms of a common mental health disorder (depression, anxiety) based on self-disclosure questionnaires (depression: CES-D=16; anxiety: GAD=5)

Exclusion criteria

Exclusion criteria: Clinical depression and/or anxiety disorder, determined by clinical interviews; Suicidality at baseline, measured by BDI II, item 9 (value > 1); Unwilling to sign the consent form; Diagnosed psychosis or dissociative symptoms; bipolare disorder in the past or present; On waiting list for psychotherapy; Psychotherapeutical treatment because of depression or anxiety in the last 6 months

Design outcomes

Primary

Measure	Time frame
Time to disorder onset of any depression and/or anxiety disorder within a follow-up period of 12 months after baseline, determined by clinical, diagnostic telephone interviews: • Psychopathology (Sections of Mini international Neuropsychiatric Interview, Mini 6.0, Sheehan, Lecrubier, 2010) at T1 baseline (pre), 6 and 12 months Follow-up (6 & 12 M-F-U); • Depressive symptoms (Inventory of depressive Symptomatology QIDS-C16, Rush, et al., 1996), at pre, post, 6 & 12 M-F-U; • Anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A, Hamilton, 1959), at pre, post, 6 & 12 M-F-U.	—

Measure

Time frame

Time to disorder onset of any depression and/or anxiety disorder within a follow-up period of 12 months after baseline, determined by clinical, diagnostic telephone interviews: • Psychopathology (Sections of Mini international Neuropsychiatric Interview, Mini 6.0, Sheehan, Lecrubier, 2010) at T1 baseline (pre), 6 and 12 months Follow-up (6 & 12 M-F-U); • Depressive symptoms (Inventory of depressive Symptomatology QIDS-C16, Rush, et al., 1996), at pre, post, 6 & 12 M-F-U; • Anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A, Hamilton, 1959), at pre, post, 6 & 12 M-F-U.

—

Secondary

Measure	Time frame
By self-report in questionnaires: • Symptom severity (e.g. depression, anxiety) by self-report in questionnaires (Center for Epidemiologic Studies Depression Scale, CES-D, Radloff, 1977; General Anxiety Disorder Measurement, GAD-7, Spitzer, Kroenke, Williams, et al., 2006) at T0, peri-treatment (peri, 4 weeks), post, 6 & 12 M-F-U; • Depressive symptoms (Patient Health Questionnaire, PHQ-9, Kroenke, Spitzer, Williams, 2001) at pre, peri, post, 6 & 12 M-F-U; • Sociodemographics (self developed) at T0 (sign-up) • Mental health (self developed) at T0 (sign-up) • Alcohol use (The Alcohol Use Disorder Identification Test, AUDIT-C, Babor et al., 2001) at pre, peri, post, 6 & 12 M-F-U; • Quality of Life (WHO-Five Wellbeing Index, WHO-5, WHO, 1998) at pre, post, 6 & 12 M-F-U; • Quality of life (EuroQol, EQ-5D, EuroQol Group, 1995) at pre, post, 6 & 12 M-F-U; • Quality of life (Assesment Quality of Life, AQol-8D, Hawthorne, Richardson & Osborne, 1999) at pre, post, 6 & 12 M-F-U; • Cost effectiveness (Client Service Receipt Inventory, CSRI, Beecham & Knapp, 1992) at pre, 6 & 12 M-F-U; • Training expectations (Credibility/Expectancy Questionnaire, CEQ, Devilly & Borkovec, 2000) at pre; • Negative effects of training (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP, Ladwig, Rief & Nestoriuc, 2014) at post; • Training satisfaction (Client Satisfaction Questionnaire, CSQ-8, Larsen, Attkisson, Hargreaves & Nguyen, 1979) at peri, post; • Training satisfaction (Adaption of the Working Alliance Inventory SR, WAI-SR, Wilmers et al., 2010) at peri; • Attitude towards psychotherapy (Attitudes Towards Seeking Professional Help, ATSPPHS, Fischer & Turner, 1970) at pre, post; • Supportive Accountability Questionnaire (self development based on Supportive Accountability Theory, Mohr et al., 2011) at peri; • Risk factors questionnaire (self developed) at pre; • Sleep quality (Pittsburgh Sleep Quality Index, PSQI, Buysse et al., 1989) at pre, post, 6 &	—

Measure

Time frame

By self-report in questionnaires: • Symptom severity (e.g. depression, anxiety) by self-report in questionnaires (Center for Epidemiologic Studies Depression Scale, CES-D, Radloff, 1977; General Anxiety Disorder Measurement, GAD-7, Spitzer, Kroenke, Williams, et al., 2006) at T0, peri-treatment (peri, 4 weeks), post, 6 & 12 M-F-U; • Depressive symptoms (Patient Health Questionnaire, PHQ-9, Kroenke, Spitzer, Williams, 2001) at pre, peri, post, 6 & 12 M-F-U; • Sociodemographics (self developed) at T0 (sign-up) • Mental health (self developed) at T0 (sign-up) • Alcohol use (The Alcohol Use Disorder Identification Test, AUDIT-C, Babor et al., 2001) at pre, peri, post, 6 & 12 M-F-U; • Quality of Life (WHO-Five Wellbeing Index, WHO-5, WHO, 1998) at pre, post, 6 & 12 M-F-U; • Quality of life (EuroQol, EQ-5D, EuroQol Group, 1995) at pre, post, 6 & 12 M-F-U; • Quality of life (Assesment Quality of Life, AQol-8D, Hawthorne, Richardson & Osborne, 1999) at pre, post, 6 & 12 M-F-U; • Cost effectiveness (Client Service Receipt Inventory, CSRI, Beecham & Knapp, 1992) at pre, 6 & 12 M-F-U; • Training expectations (Credibility/Expectancy Questionnaire, CEQ, Devilly & Borkovec, 2000) at pre; • Negative effects of training (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP, Ladwig, Rief & Nestoriuc, 2014) at post; • Training satisfaction (Client Satisfaction Questionnaire, CSQ-8, Larsen, Attkisson, Hargreaves & Nguyen, 1979) at peri, post; • Training satisfaction (Adaption of the Working Alliance Inventory SR, WAI-SR, Wilmers et al., 2010) at peri; • Attitude towards psychotherapy (Attitudes Towards Seeking Professional Help, ATSPPHS, Fischer & Turner, 1970) at pre, post; • Supportive Accountability Questionnaire (self development based on Supportive Accountability Theory, Mohr et al., 2011) at peri; • Risk factors questionnaire (self developed) at pre; • Sleep quality (Pittsburgh Sleep Quality Index, PSQI, Buysse et al., 1989) at pre, post, 6 &

—

Countries

Austria, Germany, Netherlands, Spain, Switzerland

Contacts

Public ContactKiona Weisel

Lehrstuhl für Klinische Psychologie und Psychotherapie (KliPs) Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)

kiona.weisel@fau.de09131 - 85 - 67570

Outcome results

None listed